TSXV:CIP.H

Stock Analysis Report

Canadian International Pharma

Executive Summary

Canadian International Pharma Corp. focuses on the manufacture, distribution, and sale of generic and nutraceutical drugs in Canada and internationally.

Snowflake

Fundamentals

Weak fundamentals or lack of information.

Share Price & News

How has Canadian International Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

CIP.H

-5.8%

CA Pharmaceuticals

0.3%

CA Market


1 Year Return

-66.7%

CIP.H

-58.4%

CA Pharmaceuticals

0.1%

CA Market

Return vs Industry: CIP.H underperformed the Canadian Pharmaceuticals industry which returned -58.4% over the past year.

Return vs Market: CIP.H underperformed the Canadian Market which returned 0.1% over the past year.


Shareholder returns

CIP.HIndustryMarket
7 Day0%-5.8%0.3%
30 Day0%-22.8%-2.5%
90 Day-33.3%-33.7%-1.4%
1 Year-66.7%-66.7%-58.4%-58.4%3.6%0.1%
3 Year-86.7%-86.7%85.8%84.4%14.3%4.1%
5 Year-77.8%-77.8%274.7%274.7%25.0%6.9%

Price Volatility Vs. Market

How volatile is Canadian International Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Canadian International Pharma undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Canadian International Pharma is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Canadian International Pharma has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of CIP.H’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Canadian International Pharma regulatory filings.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Canadian International Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

87.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Canadian International Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Canadian International Pharma performed over the past 5 years?

16.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CIP.H is unprofitable, but has reduced losses over the past 5 years at a rate of 16.3% per year.

Accelerating Growth: Unable to compare CIP.H's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CIP.H is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).


Return on Equity

High ROE: CIP.H's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: CIP.H is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CIP.H is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Canadian International Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: CIP.H has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CIP.H has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: CIP.H has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: CIP.H's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: CIP.H has a low level of unsold assets or inventory.

Debt Coverage by Assets: CIP.H has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CIP.H has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CIP.H has less than a year of cash runway if free cash flow continues to grow at historical rates of 55.6% each year.


Next Steps

Dividend

What is Canadian International Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.8%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate CIP.H's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CIP.H's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CIP.H's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CIP.H's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CIP.H's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Canadian International Pharma's salary, the management and board of directors tenure and is there insider trading?

5.3yrs

Average management tenure


CEO

Doug Mason (71yo)

5.3yrs

Tenure

CA$10,000

Compensation

Mr. Douglas L. Mason, also known as Doug, was Chief Executive Officer of Naturally Splendid Enterprises Ltd., from April 11, 2018 until August 2019 and was its Director from November 2017 until August 2019 ...


CEO Compensation Analysis

Compensation vs. Market: Doug's total compensation ($USD7.58K) is too low to compare against companies of similar size in the Canadian market ($USD121.56K).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.


Management Age and Tenure

5.3yrs

Average Tenure

71yo

Average Age

Experienced Management: CIP.H's management team is seasoned and experienced (5.3 years average tenure).


Board Age and Tenure

9.5yrs

Average Tenure

56yo

Average Age

Experienced Board: CIP.H's board of directors are considered experienced (9.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Doug Mason (71yo)

    Chairman & CEO

    • Tenure: 5.3yrs
    • Compensation: CA$10.00k
  • John Kowalchuk (72yo)

    Vice President of Explorations

    • Tenure: 0yrs
  • Sead Hamzagic (56yo)

    CFO, Secretary & Director

    • Tenure: 11.7yrs
    • Compensation: CA$30.00k
  • Mack Payravi

    President & Director

    • Tenure: 4.5yrs

Board Members

  • Doug Mason (71yo)

    Chairman & CEO

    • Tenure: 5.3yrs
    • Compensation: CA$10.00k
  • Sead Hamzagic (56yo)

    CFO, Secretary & Director

    • Tenure: 11.7yrs
    • Compensation: CA$30.00k
  • Andrzej Kowalski (56yo)

    Director

    • Tenure: 7.3yrs
  • Mack Payravi

    President & Director

    • Tenure: 4.5yrs
  • Doug Patterson

    Chair of the Advisory

    • Tenure: 0yrs
  • Aaron Wong

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

Canadian International Pharma Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Canadian International Pharma Corp.
  • Ticker: CIP.H
  • Exchange: TSXV
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$384.530k
  • Shares outstanding: 38.45m
  • Website: https://www.canpharmacorp.ca

Location

  • Canadian International Pharma Corp.
  • 2489 Bellevue Avenue
  • West Vancouver
  • British Columbia
  • V7V 1E1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CIP.HTSXV (TSX Venture Exchange)YesCommon SharesCACADJan 1990
BPCO.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 1990

Biography

Canadian International Pharma Corp. focuses on the manufacture, distribution, and sale of generic and nutraceutical drugs in Canada and internationally. It also provides testing and measuring services for  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:03
End of Day Share Price2019/10/11 00:00
Earnings2019/07/31
Annual Earnings2018/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.